Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis
2022-502619-13-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Fenebrutinib with Placebo (2 arms). Planned start Aug 2024; status: authorised.
02
Drugs
fenebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2022-502619-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502619-13-00.